April 26, 2016
Boehringer Ingelheim Japan said on April 25 that its ethical drug sales crept up 2% from the previous year to 256 billion yen on an NHI price basis in 2015 thanks to steady performances from its hypertension medicine Micardis (telmisartan)...read more